The short answer
Have niacinamide reviewed before using it with primidone, especially at high supplemental doses. A small human study found altered conversion of primidone to phenobarbital.
What this answer covers
Exact nicotinamide/niacinamide; not interchangeable with nicotinic acid or dietary vitamin B3 exposure.
- Supplement or preparation
- Niacinamide
- Medication ingredient
- primidone
Parent drug and metabolite are different
Primidone is active itself and also forms phenobarbital and PEMA. In the small study, nicotinamide reduced conversion toward phenobarbital, changing the parent-to-metabolite ratio. That is not the same as proving more absorption.
The human evidence is small
Only three epilepsy patients were studied. Mouse findings in that report and a separate phenobarbital experiment cannot determine a safe niacinamide dose or predict your seizure control.
Check the actual B3 product
Bring the form and daily amount to the pharmacist. No validated dosing gap prevents this potential metabolism effect, and ordinary food intake has not been shown to reproduce the studied interaction.
Keep the prescribed medicine steady
Do not stop primidone abruptly or adjust its dose to compensate for a supplement. Sudden withdrawal can provoke serious seizures. Tell the prescriber about new or worsening symptoms and all supplement changes.
Evidence and practical considerations
Absorption & effectiveness
Tiny human study supports altered primidone metabolism and parent-to-metabolite ratio, not proven increased intestinal absorption or uniform rises in all active substances.
- Exact scope
- Exact nicotinamide/niacinamide; not interchangeable with nicotinic acid or dietary vitamin B3 exposure. with Exact oral primidone; parent and metabolites distinguished; no other drug/route assumed equivalent.
- Medication form and route
- oral supplement unless pregnancy section explicitly distinguishes neonatal injection
- Timing or duration
- Preparation, dose and duration determine applicability; chronic nutrition evidence is not a single-dose interaction.
What remains uncertain
- Only three patients; abstract does not establish safe low-dose threshold or clinical benefit/harm. Quantitative mouse results cannot be assigned to patients.
Factors that may matter: exact supplement identity; dose; other medicines; clinical indication; baseline nutrition; pregnancy where relevant.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral primidone for epilepsy.
Primidone itself and its phenobarbital and PEMA metabolites have anticonvulsant activity. Drowsiness, ataxia and vertigo can occur. Rare megaloblastic anemia may respond to folic acid without stopping therapy. Label advises maternal vitamin K1 around delivery. Abrupt withdrawal can provoke status epilepticus.
How this applies: Exact RxCUI 8691 IN primidone, UNII 13AFD7670Q, oral tablets.
Parent and metabolites are distinct active exposures. Pregnancy label advice is not proof of benefit for routine prenatal vitamin K or a general adult supplement requirement.
Source 2: current product label
medicines.org.uk · Source check Sep 10, 2026
Population: Patients receiving oral primidone for epilepsy or essential tremor.
Potent CNS depressant; long-term vitamin D supplementation may be needed. Lists folates among co-treatments requiring attention; megaloblastic anemia can respond to folic acid/B12. St John’s wort is listed under contraindicated co-use because primidone concentrations and effectiveness may decrease. Maternal vitamin K1 is advised near delivery.
How this applies: Exact primidone label supports ingredient-specific boundaries rather than inference solely from phenobarbital metabolism.
Does not quantify botanical interactions or make parent and metabolite concentrations equivalent. Maternal vitamin K guidance differs from evidence reviews. No universal supplement spacing.
Source 3: original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Three epilepsy patients plus a separate mouse experiment.
Human primidone-to-phenobarbital ratio rose with nicotinamide dose, consistent with inhibited conversion. Mouse half-life and percent conversion changes are separate results.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
Tiny human sample. Abstract does not specify a safe low dose or prove increased intestinal absorption, improved seizure control, or equivalent changes in parent and metabolite concentrations.
Source 4: original animal study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Mice, not humans.
Nicotinamide potentiated phenobarbital anticonvulsant activity in some experimental seizure models.
How this applies: Apply only to the named drugs and study exposures; no unmeasured parent/metabolite or preparation equivalence.
Animal dosing, route and phenobarbital exposure cannot establish clinical primidone safety or efficacy.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact current available claims reviewed against captured originals; no clinical review asserted. | |
| Research summary published |
Article revision: 7b1f97a6efd92e8a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.